All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

In 2024, Amgen was named ... anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon (including the ...

Good afternoon, everyone, and thank you for joining us today. 2024 capped another year of strong execution at Amgen. Our operations teams supplied every patient every time. Our clinical teams ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

Over to you, Bob. Good afternoon, everyone, and thank you for joining us today. 2024 capped another year of strong execution at Amgen. Our operations teams supplied every patient every time. Our ...

Biosimilar Products Sales: $2.2 billion, a 16% year-over-year increase. Dividend: $2.25 per share in the fourth quarter, a 6% increase from 2023. Amgen Inc (NASDAQ:AMGN) reported a 19% year-over-year ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Feb. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus ... Excluding sales from our Horizon Therapeutics (Horizon ...

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

The VGChartz sales comparison series of articles are updated ... which is why there are big increases and decreases. December 2024 is the 94th month that the Nintendo Switch has been available ...